CN112076103A - 一种含有二氢杨梅素的敏感性肌肤护肤品 - Google Patents
一种含有二氢杨梅素的敏感性肌肤护肤品 Download PDFInfo
- Publication number
- CN112076103A CN112076103A CN202011041652.1A CN202011041652A CN112076103A CN 112076103 A CN112076103 A CN 112076103A CN 202011041652 A CN202011041652 A CN 202011041652A CN 112076103 A CN112076103 A CN 112076103A
- Authority
- CN
- China
- Prior art keywords
- parts
- dihydromyricetin
- skin care
- care product
- prepared
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- KJXSIXMJHKAJOD-LSDHHAIUSA-N (+)-dihydromyricetin Chemical compound C1([C@@H]2[C@H](C(C3=C(O)C=C(O)C=C3O2)=O)O)=CC(O)=C(O)C(O)=C1 KJXSIXMJHKAJOD-LSDHHAIUSA-N 0.000 title claims abstract description 182
- KQILIWXGGKGKNX-UHFFFAOYSA-N dihydromyricetin Natural products OC1C(=C(Oc2cc(O)cc(O)c12)c3cc(O)c(O)c(O)c3)O KQILIWXGGKGKNX-UHFFFAOYSA-N 0.000 title claims abstract description 91
- 230000037307 sensitive skin Effects 0.000 title claims abstract description 32
- 239000006071 cream Substances 0.000 claims abstract description 11
- 239000000839 emulsion Substances 0.000 claims abstract description 10
- 239000004480 active ingredient Substances 0.000 claims abstract description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 36
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
- 229940015975 1,2-hexanediol Drugs 0.000 claims description 20
- TXFPEBPIARQUIG-UHFFFAOYSA-N 4'-hydroxyacetophenone Chemical compound CC(=O)C1=CC=C(O)C=C1 TXFPEBPIARQUIG-UHFFFAOYSA-N 0.000 claims description 20
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 claims description 20
- 239000002253 acid Substances 0.000 claims description 15
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 claims description 15
- 230000001815 facial effect Effects 0.000 claims description 13
- 235000011187 glycerol Nutrition 0.000 claims description 13
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 claims description 10
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 10
- 239000004721 Polyphenylene oxide Substances 0.000 claims description 10
- 229920002385 Sodium hyaluronate Polymers 0.000 claims description 10
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 10
- 125000002801 octanoyl group Chemical group C(CCCCCCC)(=O)* 0.000 claims description 10
- 229920000570 polyether Polymers 0.000 claims description 10
- 229940010747 sodium hyaluronate Drugs 0.000 claims description 10
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 10
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims description 10
- 229940082500 cetostearyl alcohol Drugs 0.000 claims description 7
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 claims description 7
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 claims description 7
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 claims description 7
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 7
- 239000004006 olive oil Substances 0.000 claims description 7
- 235000008390 olive oil Nutrition 0.000 claims description 7
- -1 polydimethylsiloxane Polymers 0.000 claims description 7
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 claims description 7
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 claims description 5
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 claims description 5
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 5
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 5
- 239000004475 Arginine Substances 0.000 claims description 5
- 229920002498 Beta-glucan Polymers 0.000 claims description 5
- 102000008186 Collagen Human genes 0.000 claims description 5
- 108010035532 Collagen Proteins 0.000 claims description 5
- 229920002125 Sokalan® Polymers 0.000 claims description 5
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 5
- OWBTYPJTUOEWEK-UHFFFAOYSA-N butane-2,3-diol Chemical compound CC(O)C(C)O OWBTYPJTUOEWEK-UHFFFAOYSA-N 0.000 claims description 5
- 229960001631 carbomer Drugs 0.000 claims description 5
- 229920001436 collagen Polymers 0.000 claims description 5
- 229920001577 copolymer Polymers 0.000 claims description 5
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 5
- PKPOVTYZGGYDIJ-UHFFFAOYSA-N dioctyl carbonate Chemical compound CCCCCCCCOC(=O)OCCCCCCCC PKPOVTYZGGYDIJ-UHFFFAOYSA-N 0.000 claims description 5
- 229940075529 glyceryl stearate Drugs 0.000 claims description 5
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 5
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 claims description 5
- AEIJTFQOBWATKX-UHFFFAOYSA-N octane-1,2-diol Chemical compound CCCCCCC(O)CO AEIJTFQOBWATKX-UHFFFAOYSA-N 0.000 claims description 5
- 229940049964 oleate Drugs 0.000 claims description 5
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 5
- 229940100460 peg-100 stearate Drugs 0.000 claims description 5
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 claims description 5
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 5
- FWFUWXVFYKCSQA-UHFFFAOYSA-M sodium;2-methyl-2-(prop-2-enoylamino)propane-1-sulfonate Chemical compound [Na+].[O-]S(=O)(=O)CC(C)(C)NC(=O)C=C FWFUWXVFYKCSQA-UHFFFAOYSA-M 0.000 claims description 5
- 229940032094 squalane Drugs 0.000 claims description 5
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 claims description 5
- 229920001285 xanthan gum Polymers 0.000 claims description 5
- 239000000230 xanthan gum Substances 0.000 claims description 5
- 229940082509 xanthan gum Drugs 0.000 claims description 5
- 235000010493 xanthan gum Nutrition 0.000 claims description 5
- 235000016108 Argania sideroxylon Nutrition 0.000 claims description 3
- 241001673902 Argania spinosa Species 0.000 claims description 3
- 240000007817 Olea europaea Species 0.000 claims description 3
- 229940042585 tocopherol acetate Drugs 0.000 claims description 3
- 241001632409 Aralia elata Species 0.000 claims description 2
- 235000015888 Aralia elata Nutrition 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 description 28
- 239000000047 product Substances 0.000 description 24
- 210000003491 skin Anatomy 0.000 description 22
- 210000003630 histaminocyte Anatomy 0.000 description 21
- 230000000694 effects Effects 0.000 description 13
- 239000003642 reactive oxygen metabolite Substances 0.000 description 12
- 230000019491 signal transduction Effects 0.000 description 10
- 102000043136 MAP kinase family Human genes 0.000 description 9
- 108091054455 MAP kinase family Proteins 0.000 description 9
- 241001018563 Nekemias grossedentata Species 0.000 description 9
- 239000002537 cosmetic Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 239000000686 essence Substances 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 206010015150 Erythema Diseases 0.000 description 6
- 108010029477 STAT5 Transcription Factor Proteins 0.000 description 6
- 102000001712 STAT5 Transcription Factor Human genes 0.000 description 6
- 206010070834 Sensitisation Diseases 0.000 description 6
- 230000008313 sensitization Effects 0.000 description 6
- 206010020751 Hypersensitivity Diseases 0.000 description 5
- 102000004889 Interleukin-6 Human genes 0.000 description 5
- 108090001005 Interleukin-6 Proteins 0.000 description 5
- 230000020411 cell activation Effects 0.000 description 5
- 231100000321 erythema Toxicity 0.000 description 5
- 229940100601 interleukin-6 Drugs 0.000 description 5
- 238000002386 leaching Methods 0.000 description 5
- 230000026731 phosphorylation Effects 0.000 description 5
- 238000006366 phosphorylation reaction Methods 0.000 description 5
- 230000004913 activation Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 108010067755 dinitrophenyl-bovine serum albumin Proteins 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 238000011835 investigation Methods 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 102100029064 Serine/threonine-protein kinase WNK1 Human genes 0.000 description 3
- 102000040945 Transcription factor Human genes 0.000 description 3
- 108091023040 Transcription factor Proteins 0.000 description 3
- 102000001400 Tryptase Human genes 0.000 description 3
- 108060005989 Tryptase Proteins 0.000 description 3
- 230000000172 allergic effect Effects 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 238000007747 plating Methods 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 206010012442 Dermatitis contact Diseases 0.000 description 2
- 208000004262 Food Hypersensitivity Diseases 0.000 description 2
- 206010016946 Food allergy Diseases 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 102000042838 JAK family Human genes 0.000 description 2
- 108091082332 JAK family Proteins 0.000 description 2
- 102000019149 MAP kinase activity proteins Human genes 0.000 description 2
- 108040008097 MAP kinase activity proteins Proteins 0.000 description 2
- 208000003351 Melanosis Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 208000002029 allergic contact dermatitis Diseases 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 230000003266 anti-allergic effect Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 235000020932 food allergy Nutrition 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 208000001875 irritant dermatitis Diseases 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 2
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 1
- OSCJHTSDLYVCQC-UHFFFAOYSA-N 2-ethylhexyl 4-[[4-[4-(tert-butylcarbamoyl)anilino]-6-[4-(2-ethylhexoxycarbonyl)anilino]-1,3,5-triazin-2-yl]amino]benzoate Chemical compound C1=CC(C(=O)OCC(CC)CCCC)=CC=C1NC1=NC(NC=2C=CC(=CC=2)C(=O)NC(C)(C)C)=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=N1 OSCJHTSDLYVCQC-UHFFFAOYSA-N 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241001313857 Bletilla striata Species 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- 206010008570 Chloasma Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 206010014970 Ephelides Diseases 0.000 description 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
- 102000008379 I-kappa B Proteins Human genes 0.000 description 1
- 108010021699 I-kappa B Proteins Proteins 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 102100035792 Kininogen-1 Human genes 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 108010003541 Platelet Activating Factor Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010061481 Renal injury Diseases 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000009285 allergic inflammation Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000012085 chronic inflammatory response Effects 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003112 degranulating effect Effects 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000008798 inflammatory stress Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 208000037806 kidney injury Diseases 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 230000008832 photodamage Effects 0.000 description 1
- 230000004983 pleiotropic effect Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 230000034190 positive regulation of NF-kappaB transcription factor activity Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000002331 protein detection Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000036555 skin type Effects 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- JUJBNYBVVQSIOU-UHFFFAOYSA-M sodium;4-[2-(4-iodophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].C1=CC([N+](=O)[O-])=CC=C1N1[N+](C=2C=CC(I)=CC=2)=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=N1 JUJBNYBVVQSIOU-UHFFFAOYSA-M 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/31—Hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/342—Alcohols having more than seven atoms in an unbroken chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/35—Ketones, e.g. benzophenone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
- A61K8/375—Esters of carboxylic acids the alcohol moiety containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/42—Amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/678—Tocopherol, i.e. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
- A61K8/8141—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
- A61K8/8147—Homopolymers or copolymers of acids; Metal or ammonium salts thereof, e.g. crotonic acid, (meth)acrylic acid; Compositions of derivatives of such polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
- A61K8/817—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen; Compositions or derivatives of such polymers, e.g. vinylimidazol, vinylcaprolactame, allylamines (Polyquaternium 6)
- A61K8/8182—Copolymers of vinyl-pyrrolidones. Compositions of derivatives of such polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/86—Polyethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/89—Polysiloxanes
- A61K8/891—Polysiloxanes saturated, e.g. dimethicone, phenyl trimethicone, C24-C28 methicone or stearyl dimethicone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/005—Preparations for sensitive skin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Cosmetics (AREA)
Abstract
一种含有二氢杨梅素的敏感性肌肤护肤品，以二氢杨梅素作为缓解敏感性肌肤护肤品的活性成分，二氢杨梅素添加量为护肤品重量份的0.01～5份，包括面霜、乳液、面膜和精华液，本发明利用体外细胞实验证明二氢杨梅素可抑制过敏及炎症多条信号通路中的信号物质以实现缓解敏感性肌肤问题的效果,二氢杨梅素可以通过抑制NF‑κB通路中p65的表达抑制促炎性细胞因子的分泌，可以通过抑制抑制STAT5磷酸化抑制肥大细胞的激活，也可以通过抑制ERK1/2、p38和JNK磷酸化抑制过敏炎症应激通路。
Description
技术领域：
本发明涉及化妆品领域，具体涉及二氢杨梅素在敏感性肌肤的护肤品中的应用。
背景技术：
敏感性皮肤是一种常见的皮肤类型，指的是高反应性、耐受性差或易过敏的皮肤状态。敏感性皮肤易受到外界物理化学等因素的刺激而产生不适反应，主要表现为皮肤干燥、脱屑、发红，容易产生瘙痒、烧灼、刺痛、紧绷等。敏感性皮肤易受到外源刺激，易引发刺激性接触性皮炎(irritant contact dermatitis，ICD)和变应性接触性皮炎(allergiccontact dermatitis，ACD)，从而导致机体中组织胺、白三烯、血小板活化因子、缓激肽等的释放引发各种过敏反应症状。敏感性皮肤多见于女性面部，以及双手、头皮和足部，研究报道显示北京、上海、广州3个城市敏感性皮肤的发生率平均为13％，其中女性高于男性(兰宇贞，谢志强.敏感性皮肤研究进展[J].中国中西医结合皮肤性病学杂志,2013(12):199-201)。近年来敏感性皮肤的发生率也有不断增长的趋势，这将对人们的生活质量造成极大的影响。随着人们对化妆品需求的增加，大量新型化妆品原料，尤其一些化学物，不断被应用于化妆品开发中，使得人们接触更多潜在致敏物质，大大增加了皮肤过敏的风险。化妆品中含有的香精、防腐剂、乳化剂、抗氧化剂、防晒剂、激素(皮质类固醇激素、雌激素等)等均是刺激敏感性皮肤的风险物质。近年来人们对生活质量要求不断提升，对敏感性皮肤问题也越来越重视，因而各大护肤品品牌将抗敏抗刺激列入产品研发的重点项目之一。
二氢杨梅素(Dihydromyricetin,DHM)是藤茶中含量作为丰富的一类活性黄酮类化合物，除总黄酮的一般特性外，还具有保护心脏、抗糖尿病、保护肝脏、神经保护、抗肿瘤、保护皮肤等作用，医药中还可应用于细菌感染、骨质疏松、哮喘、肾损伤、肾毒性等的治疗。也有研究者通过小鼠食物过敏模型发现二氢杨梅素能够有效缓解小鼠过敏症状及相关过敏指标，具有良好的抗食物过敏活性。二氢杨梅素在偏酸性和中性条件下稳定，由于护肤品的pH为5～7，因而适应于二氢杨梅素稳定发挥作用。近年来，二氢杨梅素作为INCI中收录的藤茶提取物和显齿蛇葡萄叶提取物的活性成分被应用于化妆品中。研究显示，二氢杨梅素可以延缓皮肤黄褐斑和老年斑的出现时间、防治光损伤。同时，二氢杨梅素复配白芨多糖制备的化妆品具有一定的祛斑、美白等功效。目前，二氢杨梅素在抗敏抗刺激护肤品中的应用还未见报道，其具体作用机制尚不清楚。
发明内容：
针对现有技术的上述问题，本发明目的在于提供了一种含有二氢杨梅素的敏感性肌肤护肤品。
为达成上述目的，本发明采用如下技术方案：
一种含有二氢杨梅素的敏感性肌肤护肤品，所述护肤品以二氢杨梅素作为缓解敏感性肌肤护肤品的活性成分，二氢杨梅素添加量为护肤品重量份的0.01～5份。
进一步，所述护肤品为面霜，按照以下重量份配制：2,3-丁二醇1～8份，丙烯酰二甲基牛磺酸铵/VP共聚物0.1～1份，甘油聚醚-26 1～10份，二氢杨梅素0.01～5份，辛甘醇0.01～1份，1,2-己二醇0.1～2份，甘油硬脂酸酯0.1～3份，PEG-100硬脂酸酯0.1～3份，辛酸/癸酸甘油三酯1～8份，聚二甲基硅氧烷0.1～3份，刺阿干树仁1～6份，生育酚乙酸酯0.1～1份，余量为水。
进一步，所述护肤品为乳液，按照以下重量份配制：丁二醇1～10份，甘油0.1～8份，卡波姆0.01～1份，二氢杨梅素0.01～5份，对羟基苯乙酮0.1～3份，1,2-己二醇0.01～2份，辛酰羟肟酸0.01～2份，鲸蜡硬脂醇0.1～3份，碳酸二辛酯0.5～3份，角鲨烷0.1～6份，鲸蜡硬脂醇橄榄油酸1～5份，山梨坦橄榄油酸酯0.1～3份，生育酚乙酸酯0.1～1份，精氨酸0.01～2份，余量为水。
进一步，所述护肤品为面膜，按照以下重量份配制：甘油1～10份，丁二醇1～8份，透明质酸钠0.01～1份，二氢杨梅素0.01～3份，黄原胶0.01～3份，胶原溶液0.1～5份，对羟基苯乙酮0.1～3份，1,2-己二醇0.1～2份，辛酰羟肟酸0.01～1份，余量为水。
进一步，所述护肤品为精华液，按照以下重量份配制：丁二醇1～10份，甘油聚醚-26 0.5～5份，，透明质酸钠0.01～1份，二氢杨梅素0.01～5份，β-葡聚糖溶液0.1～5份，1,2-戊二醇0.1～5份，辛甘醇0.01～1份，1,2-己二醇0.01～2份份，余量为水。
进一步，所述护肤品为面霜，按照以下重量份配制：2，3-丁二醇4份，丙烯酰二甲基牛磺酸铵/VP共聚物0.4份，甘油聚醚-26 5份，二氢杨梅素0.2份，辛甘醇0.2份，1,2-己二醇0.5份，甘油硬脂酸酯1.8份，PEG-100硬脂酸酯1.2份，辛酸/癸酸甘油三酯5份，聚二甲基硅氧烷2份，刺阿干树仁4份，生育酚乙酸酯0.5份，水补足100份以常规方式制备面霜。
进一步，所述护肤品为乳液，按照以下重量份配制：丁二醇5份，甘油5份，卡波姆0.15份，二氢杨梅素0.2份，对羟基苯乙酮0.3份，1,2-己二醇0.5份，辛酰羟肟酸0.05份，鲸蜡硬脂醇1份，碳酸二辛酯2份，角鲨烷4份，鲸蜡硬脂醇橄榄油酸2.4份，山梨坦橄榄油酸酯1.6份，生育酚乙酸酯0.5份，精氨酸0.12份，水补足100份以常规方式制备乳液。
进一步，所述护肤品为面膜，按照以下重量份配制：甘油3份，丁二醇5份，透明质酸钠0.2份，二氢杨梅素0.05份，黄原胶0.1份，胶原溶液2份，对羟基苯乙酮0.3份，1,2-己二醇0.5份，辛酰羟肟酸0.05份，水补足100份以常规方式制备面膜。
进一步，所述护肤品为精华液，按照以下重量份配制：丁二醇5份，甘油聚醚-26 5份，，透明质酸钠0.3份，二氢杨梅素0.1份，β-葡聚糖溶液3份，1,2-戊二醇3份，辛甘醇0.2份，1,2-己二醇0.5份，水补足100份以常规方式制备精华液。
采用上述技术方案，本发明涉及的二氢杨梅素为藤茶提取物/显齿蛇葡萄叶提取物的主要成分，提取并经HPLC检测验证。
本发明的二氢杨梅素在敏感性肌肤护肤品中的应用，其产品包括面霜，乳液，面膜，精华液等。
本发明所述的二氢杨梅素为《已使用化妆品原料目录(2015版)》中收录的藤茶提取物/显齿蛇葡萄叶提取物中的活性成分，天然来源，安全无刺激。
本发明证实二氢杨梅素可以通过抑制NF-κB、JAK/STAT5和MAPK信号通路有效抑制过敏相关炎症介质的释放，从而缓解过敏性炎症，为实现二氢杨梅素在敏感性肌肤护肤品中的应用提供理论数据支持。
临床试验表明，持续使用本发明所述的含有二氢杨梅素的面膜可以有效缓解敏感性肌肤的面部红斑情况。
附图说明：
以下用附图对本发明详细说明：
图1为二氢杨梅素HPLC检测情况
图2为二氢杨梅素对RBL-2H3细胞活力的影响；
图3为二氢杨梅素对RBL-2H3细胞脱颗粒的影响；
图4为二氢杨梅素对RBL-2H3细胞活性氧(ROS)的影响；
图5为二氢杨梅素对KU812细胞IL-6的影响；
图6为二氢杨梅素对KU812细胞NF-κB信号通路的影响；
图7为二氢杨梅素对KU812细胞STAT5信号通路的影响；
图8为二氢杨梅素对KU812细胞MAPK信号通路的影响；
图9为面膜临床测试数据。
具体实施方式：
以下结合附图1-9及实施例对本发明详述：
下面的实施例对本发明作详细描述，但以下实施例中所公开的技术代表本发明相关人员能力范围内应用在本发明的生物学和化学领域基础技术手段；本发明实施例的描述及附图是示例性的，旨在辅助解释本发明；本发明中具体应用涉及的添加比例在有效范围内不局限于单一比例，以上均不能理解为对本发明的限制。
本发明提出《已使用化妆品原料目录(2015版)》中收录的藤茶提取物/显齿蛇葡萄叶提取物中的活性成分——二氢杨梅素在敏感性肌肤护肤品中的应用，含有该活性成分的面膜可以有效缓解敏感性肌肤的红斑情况。体外实验也进一步证实二氢杨梅素可通过抑制p65的表达抑制炎症因子的释放，可以通过抑制STAT5磷酸化抑制肥大细胞的激活，也可以通过抑制ERK1/2、p38和JNK磷酸化抑制过敏炎症应激通路。
实施例1二氢杨梅素的分离纯化及鉴定
配制浸提液：25％乙醇(含0.2％柠檬酸)。藤茶/显齿蛇葡萄叶：浸提液按照料液比＝1:8浸提。温度控制为70℃，浸提两次，每次60min。混合两次浸提液，过滤，浓缩，收集结晶，干燥，纯化，利用HPLC检测如下图所示。HPLC检测条件：色谱柱——ODS-35um(4.6×250mm)；柱温为40℃；检测波长为291nm；进样体积为5μL；流速为1mL/min；流动相A为甲醇，流动相B为0.1％磷酸水溶液，梯度洗脱。经过标品配制、线性关系考察、精密度考察、重复性考察、稳定性考察以及回收率测试等步骤，最终检测样品为二氢杨梅素，如图1所示。
实施例2二氢杨梅素对肥大细胞炎症介质释放的影响
实验方法：37℃，5％CO2条件下，10％胎牛血清和1％双抗的DMEM培养基培养RBL-2H3细胞。
37℃，5％CO2条件下，10％胎牛血清(热灭活)和1％双抗的RPMI-1640培养基培养KU812细胞
(1)细胞活力检测——铺板96孔板进行实验，1×104个细胞/孔，培养过夜，添加DHM(1-2000μM)孵育24h，加入WST-1试剂(10mol/L)，37℃孵育1h。在450nm波长下测定吸光值，测定细胞存活率。
(2)脱颗粒检测——铺板48孔板进行实验，1×106个细胞/孔，0.1μg/ml的anti-DNP-IgE敏化细胞16h，PBS清洗两次，100ng/ml的DNP-BSA刺激细胞，利用肥大细胞脱颗粒试验试剂盒说明书测定胰蛋白酶浓度。
(3)ROS检测——铺板96孔板进行实验，1×105个细胞/孔，0.1μg/ml的anti-DNP-IgE敏化细胞16h，然后添加DHM孵育24小时。更换为PBS，添加DCFH-DA(10μM)孵育30min，PBS洗涤细胞2次后，利用荧光观察和流式细胞术检测ROS。同时，采用mito SOXTM红色探针等检测ROS。
(4)细胞因子检测——铺板48孔板进行实验，1×106个细胞/孔，0.1μg/ml的anti-DNP-IgE敏化细胞16h，PBS清洗两次，100ng/ml的DNP-BSA刺激细胞，利用ELISA试剂盒检测上清液中的炎症因子。
数据处理：所有数据均计算平均标准差(SD)。利用t检验分析组间差距显著性。*p<0.05代表组间显著性差异，**p<0.01,***p<0.001代表组间极显著差异。#p<0.05代表组间显著性差异，##p<0.01,###p<0.001代表组间极显著差异。
实验结果：(1)如图2所示，DHM在1至500μM浓度下显示对RBL-2H3细胞无明显的细胞毒性。后续实验选择DHM的浓度为100μM。
(2)类胰蛋白酶是肥大细胞激活后释放的预形成因子一种丝氨酸蛋白酶，可以用作判断肥大细胞活化(脱颗粒)指标。如图3所示，低浓度的IgE敏化后DNP-BSA刺激细胞，即可激活肥大细胞，使其释放的胰蛋白酶显著增加。添加100μM的DHM可以显著降低细胞上清中的类胰蛋白酶，说明DHM可以抑制肥大细胞脱颗粒释放类胰蛋白酶。
(3)肥大细胞受到刺激后会释放活性氧(ROS)，过敏及炎症等反应发生过程中，也常常伴随着肥大细胞活性氧的升高。如图4A和4B所示，敏化刺激后的肥大细胞荧光明显增强，说明肥大细胞中的活性氧含量明显上升。添加100μM的DHM孵育24小时后，荧光反应明显减弱，说明肥大细胞中的活性氧含量下降。图4C所示，IgE和DNP刺激的肥大细胞ROS峰(红色)相比于control组(蓝色)明显右移，而添加DHM孵育后的ROS峰(紫色)相比于刺激组(红色)的峰明显左移。综上所述，说明DHM可以有效缓解肥大细胞由于过敏引起的活性氧的上升。
(4)白介素-6(IL-6)是一种多效性的促炎因子，在慢性炎症反应的发生和发展中起到重要的作用。如图5所示，低浓度的IgE敏化后DNP-BSA刺激细胞，可使细胞培养上清中的IL-6明显增加。添加100μM的DHM可以显著降低细胞上清中的IL-6，说明DHM可以抑制促炎因子的释放。
实施例3二氢杨梅素对肥大细胞信号通路的影响
实验方法：37℃，5％CO2条件下，10％胎牛血清(热灭活)和1％双抗的RPMI-1640培养基培养KU812细胞。利用胰酶将细胞消化下来，添加适量细胞裂解液，4℃，20min。利用总蛋白检测试剂盒检测裂解物的蛋白含量。利用SDS-PAGE电泳分离蛋白，将蛋白转印至PVDF膜上，经过脱脂牛奶中封闭、对应的一抗4℃孵育过夜(p53、JNK、p-JNK、p38、p-P38、ERK1/2、p-ERK1/2、p65、STAT5和pSTAT 5)，二抗在室温下孵育2h，膜显色，拍照。
实验结果：(1)核转录因子kappa B(NF-κB)是细胞中重要的转录调节因子，其活化可诱导多种基因的表达，进一步产生多种细胞因子，从而参与炎症反应。p50-p65异二聚体与IκB结合使NF-κB处于非活化状态，但是p65-p65和c-Rel-p50等二聚体可以有效促进NF-κB的诱导。如图6所示的Western图，敏化刺激后的KU812细胞内p65大量表达，100μM的DHM可以抑制细胞中p65的表达，从而抑制NF-κB的诱导活化。
(2)信号转导及转录激活因子(STATs)是关键的转录因子，活化后(如JAKs磷酸化)可以将细胞外的信号传递到细胞核内，引发相应基因的转录，进而触发细胞分化、增殖、发育、凋亡以及炎症等反应。STAT5与肥大细胞活化相关。本发明中图7所示的Western图，敏化刺激前后的KU812细胞内STAT5含量变化不大，但是敏化刺激后磷酸化SATA5(p-STAT5)明显上升，100μM的DHM可以抑制肥大细胞细胞中SATA5磷酸化，从而抑制肥大细胞活化。
(3)肥大细胞激活过程伴随着一系列信号传导通路及信号分子的级联网络，包括各类酪氨酸激酶及MAPK(Mitogen-activated protein kinase，丝裂原激活的蛋白激酶/MAP激酶)信号通路。MAPK信号通路中的ERK、JNK及p38 MAPK三条信号传导通路在过敏反应中均具有重要的调控作用。同时，MAPK通路可以被ROS激活。本发明中图8所示的Western图，用IgE敏化后的KU812细胞未刺激的MAPK信号通路分子的磷酸化水平都很低，大部分处于未磷酸化。用IgE敏化后的KU812细胞受到刺激的MAPK信号通路分子被磷酸化，p-p38和p-JNK表达上升。100μM的DHM可以抑制肥大细胞细胞中p-p38和p-JNK的表达，从而抑制肥大细胞活化。
实施例4二氢杨梅素应用于面霜
面霜：2，3-丁二醇4份，丙烯酰二甲基牛磺酸铵/VP共聚物0.4份，甘油聚醚-26 5份，二氢杨梅素0.2份，辛甘醇0.2份，1,2-己二醇0.5份，甘油硬脂酸酯1.8份，PEG-100硬脂酸酯1.2份，辛酸/癸酸甘油三酯5份，聚二甲基硅氧烷2份，刺阿干树仁4份，生育酚乙酸酯0.5份，水补足100份，制备面霜。
实施例5二氢杨梅素应用于乳液
乳液：丁二醇5份，甘油5份，卡波姆0.15份，二氢杨梅素0.2份，对羟基苯乙酮0.3份，1,2-己二醇0.5份，辛酰羟肟酸0.05份，鲸蜡硬脂醇1份，碳酸二辛酯2份，角鲨烷4份，鲸蜡硬脂醇橄榄油酸2.4份，山梨坦橄榄油酸酯1.6份，生育酚乙酸酯0.5份，精氨酸0.12份，水补足100份，制备乳液。
实施例6二氢杨梅素应用于面膜
面膜：甘油3份，丁二醇5份，透明质酸钠0.2份，二氢杨梅素0.05份，黄原胶0.1份，胶原溶液2份，对羟基苯乙酮0.3份，1,2-己二醇0.5份，辛酰羟肟酸0.05份，水补足100份，制备面膜。
实施例7二氢杨梅素应用于精华液
精华液：丁二醇5份，甘油聚醚-26 5份，，透明质酸钠0.3份，二氢杨梅素0.1份，β-葡聚糖溶液3份，1,2-戊二醇3份，辛甘醇0.2份，1,2-己二醇0.5份，水补足100份，制备精华液。
实施例8面膜临床评估
试验方法：以本发明实施例6所述的面膜为例，测试其功效，进行了以下临床实验研究：
征召年龄在20至60的女性志愿者(敏感性肌肤)20名，所有受试者均被告知本次研究的详细内容，并签署由安泰医疗合作安泰天盛纪念医院(TSMH)机构审查委员会批准的知情同意书。
本测试要求试验者停止使用其他抗敏类护肤品，使用本发明中实施例6的面膜样品，每天一次，连续使用28天。利用Dual-MPA 580皮肤测试系统对皮肤进行无创检测。
试验结果：20位试验者连续使用本发明中实施例6的面膜28天后，分区检测面部红斑情况(左脸/右脸/前额)。如下图9所示，试用者整体面部红斑情况均有所改善。说明二氢杨梅素在改善面部红斑情况缓解敏感性肌肤方面有效果。
上述说明示出并描述了本发明的优选实施例，如前所述，应当理解本发明并非局限于本文所披露的形式，不应看作是对其他实施例的排除，而可用于各种其他组合、修改和环境，并能够在本文所述发明构想范围内，通过上述教导或相关领域的技术或知识进行改动。而本领域人员所进行的改动和变化不脱离本发明的精神和范围，则都应在本发明所附权利要求的保护范围内。
Claims (9)
1.一种含有二氢杨梅素的敏感性肌肤护肤品，其特征在于，所述护肤品以二氢杨梅素作为缓解敏感性肌肤护肤品的活性成分，二氢杨梅素添加量为护肤品重量份的0.01～5份。
2.如权利要求1所述的一种含有二氢杨梅素的敏感性肌肤护肤品，其特征在于，所述护肤品为面霜，按照以下重量份配制：2,3-丁二醇1～8份，丙烯酰二甲基牛磺酸铵/VP共聚物0.1～1份，甘油聚醚-26 1～10份，二氢杨梅素0.01～5份，辛甘醇0.01～1份，1,2-己二醇0.1～2份，甘油硬脂酸酯0.1～3份，PEG-100硬脂酸酯0.1～3份，辛酸/癸酸甘油三酯1～8份，聚二甲基硅氧烷0.1～3份，刺阿干树仁1～6份，生育酚乙酸酯0.1～1份，余量为水。
3.如权利要求1所述的一种含有二氢杨梅素的敏感性肌肤护肤品，其特征在于，所述护肤品为乳液，按照以下重量份配制：丁二醇1～10份，甘油0.1～8份，卡波姆0.01～1份，二氢杨梅素0.01～5份，对羟基苯乙酮0.1～3份，1,2-己二醇0.01～2份，辛酰羟肟酸0.01～2份，鲸蜡硬脂醇0.1～3份，碳酸二辛酯0.5～3份，角鲨烷0.1～6份，鲸蜡硬脂醇橄榄油酸1～5份，山梨坦橄榄油酸酯0.1～3份，生育酚乙酸酯0.1～1份，精氨酸0.01～2份，余量为水。
4.如权利要求1所述的一种含有二氢杨梅素的敏感性肌肤护肤品，其特征在于，所述护肤品为面膜，按照以下重量份配制：甘油1～10份，丁二醇1～8份，透明质酸钠0.01～1份，二氢杨梅素0.01～3份，黄原胶0.01～3份，胶原溶液0.1～5份，对羟基苯乙酮0.1～3份，1,2-己二醇0.1～2份，辛酰羟肟酸0.01～1份，余量为水。
5.如权利要求1所述的一种含有二氢杨梅素的敏感性肌肤护肤品，其特征在于，所述护肤品为精华液，按照以下重量份配制：丁二醇1～10份，甘油聚醚-26 0.5～5份，，透明质酸钠0.01～1份，二氢杨梅素0.01～5份，β-葡聚糖溶液0.1～5份，1,2-戊二醇0.1～5份，辛甘醇0.01～1份，1,2-己二醇0.01～2份份，余量为水。
6.如权利要求2所述的一种含有二氢杨梅素的敏感性肌肤护肤品，其特征在于，所述护肤品为面霜，按照以下重量份配制：2，3-丁二醇4份，丙烯酰二甲基牛磺酸铵/VP共聚物0.4份，甘油聚醚-26 5份，二氢杨梅素0.2份，辛甘醇0.2份，1,2-己二醇0.5份，甘油硬脂酸酯1.8份，PEG-100硬脂酸酯1.2份，辛酸/癸酸甘油三酯5份，聚二甲基硅氧烷2份，刺阿干树仁4份，生育酚乙酸酯0.5份，水补足100份以常规方式制备面霜。
7.如权利要求3所述的一种含有二氢杨梅素的敏感性肌肤护肤品，其特征在于，所述护肤品为乳液，按照以下重量份配制：丁二醇5份，甘油5份，卡波姆0.15份，二氢杨梅素0.2份，对羟基苯乙酮0.3份，1,2-己二醇0.5份，辛酰羟肟酸0.05份，鲸蜡硬脂醇1份，碳酸二辛酯2份，角鲨烷4份，鲸蜡硬脂醇橄榄油酸2.4份，山梨坦橄榄油酸酯1.6份，生育酚乙酸酯0.5份，精氨酸0.12份，水补足100份以常规方式制备乳液。
8.如权利要求4所述的一种含有二氢杨梅素的敏感性肌肤护肤品，其特征在于，所述护肤品为面膜，按照以下重量份配制：甘油3份，丁二醇5份，透明质酸钠0.2份，二氢杨梅素0.05份，黄原胶0.1份，胶原溶液2份，对羟基苯乙酮0.3份，1,2-己二醇0.5份，辛酰羟肟酸0.05份，水补足100份以常规方式制备面膜。
9.如权利要求5所述的一种含有二氢杨梅素的敏感性肌肤护肤品，其特征在于，所述护肤品为精华液，按照以下重量份配制：丁二醇5份，甘油聚醚-26 5份，，透明质酸钠0.3份，二氢杨梅素0.1份，β-葡聚糖溶液3份，1,2-戊二醇3份，辛甘醇0.2份，1,2-己二醇0.5份，水补足100份以常规方式制备精华液。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011041652.1A CN112076103A (zh) | 2020-09-28 | 2020-09-28 | 一种含有二氢杨梅素的敏感性肌肤护肤品 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011041652.1A CN112076103A (zh) | 2020-09-28 | 2020-09-28 | 一种含有二氢杨梅素的敏感性肌肤护肤品 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112076103A true CN112076103A (zh) | 2020-12-15 |
Family
ID=73739995
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011041652.1A Pending CN112076103A (zh) | 2020-09-28 | 2020-09-28 | 一种含有二氢杨梅素的敏感性肌肤护肤品 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112076103A (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114601743A (zh) * | 2022-03-22 | 2022-06-10 | 宝萃生物科技有限公司 | 一种二氢杨梅素脂质体及其制备和应用 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105662905A (zh) * | 2016-01-20 | 2016-06-15 | 广东天键生物科技有限公司 | 二氢杨梅素在制备防治皮肤光损伤护肤品或药品中的用途 |
| CN108852893A (zh) * | 2018-08-24 | 2018-11-23 | 恩施西特优生态农业开发有限公司 | 茶多酚面膜及其制备方法 |
| CN109288760A (zh) * | 2018-11-27 | 2019-02-01 | 广东中测食品化妆品安全评价中心有限公司 | 一种植物精粹面霜及其制备方法 |
-
2020
- 2020-09-28 CN CN202011041652.1A patent/CN112076103A/zh active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105662905A (zh) * | 2016-01-20 | 2016-06-15 | 广东天键生物科技有限公司 | 二氢杨梅素在制备防治皮肤光损伤护肤品或药品中的用途 |
| CN108852893A (zh) * | 2018-08-24 | 2018-11-23 | 恩施西特优生态农业开发有限公司 | 茶多酚面膜及其制备方法 |
| CN109288760A (zh) * | 2018-11-27 | 2019-02-01 | 广东中测食品化妆品安全评价中心有限公司 | 一种植物精粹面霜及其制备方法 |
Non-Patent Citations (1)
| Title |
|---|
| 冯涵 等: "藤茶中黄酮类成分的功效研究进展", 《公共卫生与预防医学》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114601743A (zh) * | 2022-03-22 | 2022-06-10 | 宝萃生物科技有限公司 | 一种二氢杨梅素脂质体及其制备和应用 |
| CN114601743B (zh) * | 2022-03-22 | 2022-09-13 | 宝萃生物科技有限公司 | 一种二氢杨梅素脂质体及其制备和应用 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6215364B2 (ja) | ＭＣ−１Ｒ、ＭＣ−２Ｒ、およびμオピオイド受容体調節 | |
| TW200306209A (en) | Medicament for curing itching rough skin or sensitive skin and for skin whitening based on reducing production and/or release of stem cell factor | |
| US10588931B2 (en) | Daphne laureola extracts in the treatment of dermopathies | |
| CN112641692B (zh) | 一种抗敏修复组合物及其制备方法与应用 | |
| CN112076103A (zh) | 一种含有二氢杨梅素的敏感性肌肤护肤品 | |
| KR101655146B1 (ko) | 식물 당단백질 추출물을 함유하는 조성물 | |
| CN111494466A (zh) | 一种含大麻提取物的外用组合物及其应用 | |
| KR102063686B1 (ko) | 콩뿌리 추출물을 함유하는 피부 외용제 조성물 | |
| KR20180082177A (ko) | 사카로미세스 효모발효여과물, 아스파라거스줄기 추출물 및 관동꽃 추출물을 포함하는 화장료 조성물 | |
| CN110664679B (zh) | 一种具有美白抗衰老功效的中药组合物及其制备方法和应用 | |
| CN112999247A (zh) | 一种灵芝孢子粉酶解物的制备与提取工艺及其产品和应用 | |
| CN112386655A (zh) | 大白蝴蝶兰萃取物用于制备抗醣化与改善皮肤外观的组合物的用途 | |
| KR20130088665A (ko) | 생강 초임계 추출물 및 발효 미나리 박 추출물을 함유하는 식품 조성물, 화장료 조성물 및 약학 조성물 | |
| CN112315878A (zh) | 一种抗敏舒缓修复的中药复合提取物及其制备方法和应用 | |
| KR100566424B1 (ko) | 베툴린을 함유하는 피부 주름개선 화장료 조성물 | |
| CN108324603B (zh) | 一种含有松花粉提取物的化妆品及其制备工艺 | |
| CN104394867B (zh) | 含有嘌呤衍生物或其盐的用于预防或治疗过敏性皮肤炎的组合物 | |
| CN116725920A (zh) | 提高护肤品的抗红血丝或防晒功能的方法和应用 | |
| KR101715202B1 (ko) | 식물 당단백질 추출물을 함유하는 조성물 | |
| TWI712416B (zh) | 南美蟛蜞菊的萃取物用於抗皮膚發炎及促進角質細胞增生的用途 | |
| CN115105448B (zh) | 防辐射、活血养颜、抗衰老的护肤品原料制备方法及其应用 | |
| KR102416652B1 (ko) | 미세먼지로 인한 피부자극 완화 및 피부 개선용 화장료 조성물 | |
| KR102444743B1 (ko) | 피부외용제 조성물 | |
| KR102517760B1 (ko) | 피부외용제 조성물 | |
| US20240033315A1 (en) | Composition having functions of moisturizing, repairing and whitening and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB03 | Change of inventor or designer information | ||
| CB03 | Change of inventor or designer information |
Inventor after: Xiao Zizhi Inventor after: Zhang Congmin Inventor after: Huang Huijun Inventor after: Wang Xili Inventor after: Zhang Yafen Inventor after: Gao Yuanyuan Inventor after: Pan Fawu Inventor after: Rao Huanwen Inventor before: Xiao Zizhi Inventor before: Wang Xili Inventor before: Zhang Yafen Inventor before: Gao Yuanyuan Inventor before: Pan Fawu Inventor before: Rao Huanwen |
|
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20201215 |